Related Experiment Videos
Treatment of intraabdominal infection with moxalactam
Abstract:
Forty-eight case report forms for patients with cultures positive for intraabdominal infection treated with moxalactam were reviewed. The infections included abscess or peritonitis due to appendicitis (26); intraabdominal abscess of other causes (7); peritonitis due to bowel perforation (6), bowel infarction (5), or salpingitis (3); and gangrenous cholecystitis (1). Cultures of peritoneal fluid or abscess contents were performed for all patients. Seventy-eight aerobes and 118 anaerobes were isolated from the 48 patients. Thirty-eight patients (79.2%) were cured, therapy failed in nine (18.8%), and one (2%) developed fatal superinfection with Candida. The nine patients for whom treatment failed had a higher frequency of resistant anaerobes in their initial cultures (59%) than did the patients who were cured (29%; P = 0.036). An enterococcal isolate appeared to play a role in at least one treatment failure. There were no serious adverse reactions; eosinophilia (greater than 500 eosinophils/mm3) occurred in 17.4% of the patients, and phlebitis at the intravenous administration site occurred in one patient. Thus moxalactam shows promise as a single agent for the treatment of intraabdominal infections.
Insights
Moxalactam shows promise for treating intraabdominal infections, with a 79.2% cure rate. Treatment failure was linked to resistant anaerobes, highlighting the importance of microbial susceptibility in patient outcomes.
Area of Science:
- Infectious Diseases
- Pharmacology
- Microbiology
Background:
- Intraabdominal infections are a significant cause of morbidity and mortality.
- Effective antimicrobial therapy is crucial for managing these complex infections.
- Moxalactam is a newer antibiotic with broad-spectrum activity.
Purpose of the Study:
- To evaluate the efficacy and safety of moxalactam as a single agent for treating intraabdominal infections.
- To identify factors associated with treatment success or failure.
Main Methods:
- Retrospective review of 48 case report forms for patients with intraabdominal infections treated with moxalactam.
- Analysis of microbial cultures (aerobes and anaerobes) and patient outcomes (cure, failure, superinfection).
- Statistical comparison of anaerobic resistance rates between cured and failed treatment groups.
Main Results:
- Moxalactam achieved a 79.2% cure rate in 48 patients with various intraabdominal infections.
- Treatment failure (18.8%) was significantly associated with a higher frequency of resistant anaerobes (59% vs. 29%, P = 0.036).
- No serious adverse reactions were reported; eosinophilia and phlebitis were infrequent.
Conclusions:
- Moxalactam demonstrates potential as a single-agent therapy for intraabdominal infections.
- Initial anaerobic bacterial resistance is a key factor predicting treatment outcomes.
- Further investigation into moxalactam's role in managing intraabdominal infections is warranted.